Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar
The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.
· 9/4/2026, 9:41:06 AM· 2 min read
The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.
Read original story →Related stories
business
Stock up on food to prepare for extreme weather, minister warns
business
The Ayurveda Co shuts down: founders confirm ₹250 crore venture’s closure after rapid expansion
business
Italy’s market regulator approves Tata Motors unit’s offer to acquire Iveco common shares
business